Teneligliptin (CAS 760937-92-6 (free base))
See product citations (1)
Alternate Names:
Tenelia; ((2S,4S)-4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone
CAS Number:
760937-92-6 (free base)
Molecular Weight:
426.58
Molecular Formula:
C22H30N6OS
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Teneligliptin is a compound used in research studies to understand the enzyme dipeptidyl peptidase-4 (DPP-4) and its role in the regulation of incretin hormones. Researchers utilize Teneligliptin to investigate the enzyme′s influence on glucose homeostasis and insulin secretion. In biochemical studies, it serves as a tool to dissect the kinetics and inhibition mechanism of DPP-4. Furthermore, Teneligliptin is employed in the study of signal transduction pathways involved in the incretin system. It also provides a basis for comparative analyses of DPP-4 inhibitors, where its binding affinity and specificity can be contrasted with other compounds targeting the same enzyme.
Teneligliptin (CAS 760937-92-6 (free base)) References
- Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. | Kishimoto, M. 2013. Diabetes Metab Syndr Obes. 6: 187-95. PMID: 23671395
- Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis. | Okuda, Y., et al. 2016. Int J Gen Med. 9: 65-71. PMID: 27110135
- Teneligliptin in management of type 2 diabetes mellitus. | Sharma, SK., et al. 2016. Diabetes Metab Syndr Obes. 9: 251-60. PMID: 27574456
- Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy. | Abubaker, M., et al. 2017. J Clin Diagn Res. 11: OE05-OE09. PMID: 28273997
- Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. | De Nigris, V., et al. 2018. Oncotarget. 9: 8898-8910. PMID: 29507662
- Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury. | Zhang, Z., et al. 2019. Biomed Pharmacother. 109: 468-474. PMID: 30399583
- The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. | Ceriello, A., et al. 2019. Drugs. 79: 733-750. PMID: 30982160
- Teneligliptin inhibits lipopolysaccharide-induced cytotoxicity and inflammation in dental pulp cells. | Liu, X., et al. 2019. Int Immunopharmacol. 73: 57-63. PMID: 31078926
- Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor. | Sharma, S., et al. 2020. Mini Rev Med Chem. 20: 1091-1100. PMID: 32107992
- Teneligliptin inhibits IL-1β-induced degradation of extracellular matrix in human chondrocytes. | Gao, F., et al. 2020. J Cell Biochem. 121: 4450-4457. PMID: 32162384
- Teneligliptin protects against ischemia/reperfusion-induced endothelial permeability in vivo and in vitro. | Zhang, L., et al. 2020. RSC Adv. 10: 3765-3774. PMID: 35492650
- Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study. | Becerir, T., et al. 2022. Cureus. 14: e23871. PMID: 35530894
- The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle. | Li, H., et al. 2022. Eur J Pharmacol. 935: 175305. PMID: 36183856
- Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes. | Pelluri, R., et al. 2023. J Endocrinol Invest. 46: 855-867. PMID: 36624224
Inhibitor of:
CD26, DPEP3, DPP10, DPPA4, GFOD1, and PPAR gamma.Activator of:
BCS1L, and TMEM175.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Teneligliptin, 25 mg | sc-475074 | 25 mg | $260.00 |